Gilead Sciences is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It is also engaged in drug development research aimed at treating cancer. The company was founded in 1987.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Gilead Sciences news
08.11.2023
Gilead Sciences' GAAP net income for 9 months of 2023 was $4.196 billion, up 43.1% from $2.933 billion in the prior year. Revenues increased 0.5% to $20 billion from $19.892 billion a year earlier.
Source: 
investors.gilead.com
investors.gilead.com
08.11.2023
Gilead Sciences Board of Directors announced a quarterly dividend of $0.75 per share. The last day to buy securities to receive the dividend is December 13, 2023. The annual dividend yield may reach 3.8%.
Source: investors.gilead.com
investors.gilead.com
04.08.2023
Gilead Sciences' GAAP net income for 6 months of 2023 was $2.024 billion, up 76.5% from $1.147 billion in the prior year. Revenue increased 0.8% to $12.951 billion from $12.85 billion a year earlier.
Source: s29.q4cdn.com
28.04.2023
Gilead Sciences Board of Directors announced a quarterly dividend of $0.75 per share. last day to buy securities to receive the dividend is June 13, 2023. Annual dividend yield may reach 3.76%.
Source: investors.gilead.com
investors.gilead.com
General information
| Company name | Gilead Sciences |
|---|---|
| Tags | #biotechnology, #s&p500 index |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 333 LAKESIDE DR FOSTER CITY CA 94404 6505743000 |
| Mailing address | 333 LAKESIDE DR FOSTER CITY CA 94404 |
| Website | www.gilead.com |
| Information disclosure | www.sec.gov |
English (US) 